Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study

Diabetes Research and Clinical Practice

Volumn 103, Issue 3, 2014, Pages

  Takai, Masahiko ^a   Ishikawa, Masashi ^a   Maeda, Hajime ^a   Kanamori, Akira ^a   Kubota, Akira ^a   Amemiya, Hikaru ^a   Iizuka, Takashi ^a   Iemitsu, Kotaro ^a   Iwasaki, Tomoyuki ^a   Uehara, Goro ^a   Umezawa, Shinichi ^a   Obana, Mitsuo ^a   Kaneshige, Hideaki ^a   Kaneshiro, Mizuki ^a   Kawata, Takehiro ^a   Sasai, Nobuo ^a   Saito, Tatsuya ^a   Takuma, Tetsuo ^a   Takeda, Hiroshi ^a   Tanaka, Keiji ^a   Tsurui, Nobuaki ^a   Nakajima, Shigeru ^a   Hoshino, Kazuhiko ^a   Honda, Shin ^a   Machimura, Hideo ^a   Matoba, Kiyokazu ^a   Minagawa, Fuyuki ^a   Minami, Nobuaki ^a   Miyairi, Yukiko ^a   Mokubo, Atsuko ^a   Motomiya, Tetsuya ^a   Waseda, Manabu ^a   Miyakawa, Masaaki ^a   Naka, Yoshikazu ^a   Terauchi, Yasuo ^b   Tanaka, Yasushi ^c   Matsuba, Ikuro ^a   more..

^a Kanagawa Health Service Association   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycemic control; Insulin; Sitagliptin; Type 2 diabetes

Indexed keywords

GLYCEMIC CONTROL; INSULIN; SITAGLIPTIN; TYPE 2 DIABETES;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84898869563     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.045     Document Type: Article

References (10)

1. Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
2. Kadowaki T., Tajima N., Odawara M., Minamide T., Kawashima M., Yanagida D., et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int 2013, (March). [Epub ahead of print].
3. Hong E.S., Khang A.R., Yoon J.W., Kang S.M., Choi S.H., Park K.S., et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab 2012, 14(9):795-802.
4. Katsuno T., Ikeda H., Ida K., Miyagawa J.I., Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J 2013, (February). [Epub ahead of print].
5. Ellis S.L., Moser E.G., Snell-Bergeon J.K., Rodionova A.S., Hazenfield R.M., Garg S.K. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011, 28(10):1176-1181.
6. Kielgast U., Krarup T., Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34(7):1463-1468.
7. Matsuba I., Saito K., Takai M., Hirao K., Sone H. Japan diabetes clinical data management study group fasting insulin levels and metabolic risk factors in type 2 diabetic patients at the first visit in Japan: a 10-year, nationwide, observational study (JDDM 28). Diabetes Care 2012, 35(9):1853-1857.
8. Park H., Park C., Kim Y., Rascati K.L. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012, 46(11):1453-1469.
9. Maeda H., Kubota A., Tanaka Y., Terauchi Y., Matsuba I. ASSET-K Study group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012, 95(1):e20-e22.
10. Kubota A., Maeda H., Kanamori A., Matoba K., Jin Y., Minagawa F., et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012, 4(5):309-313.